Vir director Sato exercises options, sells shares

Vir Biotechnology director Vicki L. Sato reported option exercises and related share sales.

Accepted by SEC EDGAR 02/26/2026 - 04:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology director Vicki L. Sato reported option exercises and related share sales. She exercised a stock option for 42,377 shares of common stock at a price of $1.485 per share and received common shares upon exercise.

On the same date, she sold 42,377 common shares in open-market transactions, including 42,177 shares at a weighted average price of $9.7521 per share and 200 shares at $10.26 per share. The weighted-average sale involved multiple trades between $9.23 and $10.20 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025. After these transactions, she directly owned 1,144,391 Vir Biotechnology common shares.

Insider Trade Summary

Exercise and Sale: 42,377 shares ($350K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider SATO VICKI L

Role Director

Sold 42,377 shs ($413K)

Approx. gross sale proceeds $413K

Approx. exercise cost $63K

Approx. pre-tax spread $350K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	42,377	$0.00	$0.00
Exercise	Common Stock	42,377	$1.485	$63K
Sale	Common Stock	42,177	$9.7521	$411K
Sale	Common Stock	200	$10.26	$2K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 1,144,391 shares (Direct)

Footnotes (3)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. F3. Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vir Biotechnology (VIR) director Vicki L. Sato report in this Form 4?

Vicki L. Sato reported exercising stock options and selling common shares. She exercised options for 42,377 shares at $1.485 each and sold 42,377 shares in open-market trades, ending with direct ownership of 1,144,391 Vir Biotechnology shares.

How many Vir Biotechnology (VIR) shares did Vicki L. Sato sell and at what prices?

She sold 42,377 Vir Biotechnology common shares. This included 42,177 shares at a weighted average price of $9.7521 within a $9.23–$10.20 range, plus 200 shares at $10.26 per share in separate open‑market transactions reported in the Form 4.

What option exercise did Vicki L. Sato report for Vir Biotechnology (VIR)?

She exercised a stock option covering 42,377 Vir Biotechnology shares at $1.485 per share. The option had vested in 36 equal monthly installments starting October 5, 2017, resulting in the acquisition of common shares before the reported sales.

Was the Vir Biotechnology (VIR) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were made under a Rule 10b5-1 trading plan. This plan was adopted by Vicki L. Sato on March 27, 2025, providing a pre-arranged framework for executing the reported stock sales automatically.

How many Vir Biotechnology (VIR) shares does Vicki L. Sato own after these transactions?

After the reported option exercise and subsequent sales, Vicki L. Sato directly owns 1,144,391 Vir Biotechnology common shares. This figure reflects the net position following exercising 42,377 options and selling an equal number of common shares on the transaction date.

What price range did Vir Biotechnology (VIR) shares sell for in the weighted-average transaction?

The weighted-average sale price of $9.7521 reflects multiple trades between $9.23 and $10.20 per share. The Form 4 notes that detailed breakdowns of shares sold at each price within this range are available from the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		M		42,377	A	$1.485	1,186,768	D
Common Stock	02/24/2026		S(1)		42,177	D	$9.7521(2)	1,144,591	D
Common Stock	02/24/2026		S(1)		200	D	$10.26	1,144,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.485	02/24/2026		M			42,377	(3)	10/05/2027	Common Stock	42,377	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.